Group 1 - The core point of the article is that Baipusais (301080.SZ) plans to issue H-shares and list on the Hong Kong Stock Exchange to further promote its internationalization strategy [1] - The company's board has authorized management to initiate preparatory work for the H-share issuance and listing, although specific details are yet to be determined [1] Group 2 - Baipusais focuses on the biotechnology sector, primarily engaged in the research, production, and sales of biopharmaceuticals, aiming to provide high-quality biological products and services for the healthcare industry [3] - The company is involved in innovative applications of biotechnology, with its main products and services targeting early detection and validation of drugs for diseases such as tumors, autoimmune diseases, cardiovascular diseases, and infectious diseases [3] - According to the Q3 2025 report, Baipusais reported a revenue of 613 million yuan, a year-on-year increase of 32.3%; net profit attributable to shareholders was 132 million yuan, up 58.6%; and net profit excluding non-recurring items was 133 million yuan, an increase of 58.8% [3] - The operating cash flow net amount was 177 million yuan, reflecting a growth of 99.5%; the earnings per share (EPS) was 0.789 yuan [3]
百普赛斯拟港股IPO 前三季度营收超6亿元